-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Roche today announced that the European Medicines Management Agency (EMA) Committee for Medicinal human use (CHMP) has recommended approval Evrysdi ™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) 2 months and older patients who suffer Type 1, Type 2, or Type 3 or one to four SMN2 copies of SMA.
management
SMA is the main genetic cause of infant death, and 5q SMA is the most common form of the disease.
CHMP recommendations are based on data from FIREFISH clinical studies.
In FIREFISH, according to the Bayley scale's total exercise scale assessment, 29% (12/41) of infants treated with Evrysdi for 12 months were able to sit for at least five seconds without support.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here